PE20190476A1 - Compuestos sulfonimidoilpurinona 7-sustituidos y derivados para el tratamiento y la profilaxis de la infeccion virica - Google Patents

Compuestos sulfonimidoilpurinona 7-sustituidos y derivados para el tratamiento y la profilaxis de la infeccion virica

Info

Publication number
PE20190476A1
PE20190476A1 PE2019000346A PE2019000346A PE20190476A1 PE 20190476 A1 PE20190476 A1 PE 20190476A1 PE 2019000346 A PE2019000346 A PE 2019000346A PE 2019000346 A PE2019000346 A PE 2019000346A PE 20190476 A1 PE20190476 A1 PE 20190476A1
Authority
PE
Peru
Prior art keywords
alkyl
benzyl
treatment
substituted
compounds
Prior art date
Application number
PE2019000346A
Other languages
English (en)
Inventor
Lu Gao
Chungen Liang
Hongying Yun
Xiufang Zheng
Jianping Wang
Kun Miao
Bo Zhang
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of PE20190476A1 publication Critical patent/PE20190476A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/24—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 one nitrogen and one sulfur atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Se refiere a nuevos derivados sulfonimidoilpurinonas, compuestos de formula (I): en la que R1 es alquilo C1-C6, entre otros; R2 es bencilo, estando dicho bencilo no sustituido o sustituidos seleccionados independientemente entre halogeno y alquilo C1-C6, entre otros; y R3 es -NR4R5, entre otros, R4 es alquilo C1-C6, R5 es (alquil C1-C6)2NCOO-alquiloC1-C6. Son compuestos preferidos de entre: 6-amino-9-bencil-N-metil-8-oxo-N-propil-2-(propilsulfonimidoil)purin-7-carboxamida; 6-amino-9-bencil-N-(2-metoxietil)-N-metil-8-oxo-2-(propilsulfonimidoil)purin-7-carboxamida. Dichos compuestos presentan actividad agonista de receptor de tipo Toll in vivo que detectan patogenos invasores y el posterior inicio de respuestas inmunologicas innatas; tambien se refiere a una composicion farmaceutica y es util en el tratamiento o la prevencion de enfermedades infecciosas como VHB o VHC.
PE2019000346A 2016-08-29 2017-08-28 Compuestos sulfonimidoilpurinona 7-sustituidos y derivados para el tratamiento y la profilaxis de la infeccion virica PE20190476A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN2016097140 2016-08-29
CN2017092653 2017-07-12

Publications (1)

Publication Number Publication Date
PE20190476A1 true PE20190476A1 (es) 2019-04-04

Family

ID=59738346

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2019000346A PE20190476A1 (es) 2016-08-29 2017-08-28 Compuestos sulfonimidoilpurinona 7-sustituidos y derivados para el tratamiento y la profilaxis de la infeccion virica

Country Status (31)

Country Link
US (3) US10233184B2 (es)
EP (2) EP3504210B1 (es)
JP (2) JP7013467B2 (es)
KR (2) KR102459155B1 (es)
CN (1) CN109641904B (es)
AU (3) AU2017320742B2 (es)
BR (1) BR112019003519A2 (es)
CA (1) CA3034148A1 (es)
CL (1) CL2019000512A1 (es)
CO (1) CO2019000932A2 (es)
CR (1) CR20190087A (es)
DK (1) DK3504210T3 (es)
ES (1) ES2867849T3 (es)
HR (1) HRP20210621T1 (es)
HU (1) HUE053944T2 (es)
IL (3) IL293475A (es)
MA (1) MA46038B1 (es)
MX (2) MX2019002129A (es)
MY (1) MY197408A (es)
NZ (1) NZ750604A (es)
PE (1) PE20190476A1 (es)
PH (1) PH12019500432A1 (es)
PL (1) PL3504210T3 (es)
PT (1) PT3504210T (es)
RS (1) RS61752B1 (es)
RU (1) RU2751349C2 (es)
SG (2) SG11201901633WA (es)
SI (1) SI3504210T1 (es)
TW (1) TWI671300B (es)
UA (1) UA124270C2 (es)
WO (1) WO2018041763A1 (es)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2982704C (en) * 2015-05-08 2023-10-24 F. Hoffmann-La Roche Ag Sulfonimidoylpurinone compounds and derivatives for the treatment and prophylaxis of virus infection
JP7013467B2 (ja) * 2016-08-29 2022-01-31 エフ．ホフマン－ラ ロシュ アーゲー ウイルス感染の治療又は予防用の７位置換スルホンイミドイルプリノン化合物
JP7101663B2 (ja) * 2016-09-13 2022-07-15 エフ．ホフマン－ラ ロシュ アーゲー Ｔｌｒ７アゴニストとｈｂｖキャプシドアセンブリ阻害剤の併用療法
WO2019155042A1 (en) 2018-02-12 2019-08-15 F. Hoffmann-La Roche Ag Novel sulfone compounds and derivatives for the treatment and prophylaxis of virus infection
KR20200128414A (ko) * 2018-02-28 2020-11-12 에프. 호프만-라 로슈 아게 간암의 치료 및 예방을 위한 7-치환된 설폰이미도일퓨린온 화합물 및 유도체
US20200113912A1 (en) 2018-09-12 2020-04-16 Silverback Therapeutics, Inc. Methods and Compositions for the Treatment of Disease with Immune Stimulatory Conjugates
JP7287708B2 (ja) 2019-02-08 2023-06-06 プロジェニア インコーポレイテッド Ｔｏｌｌ－ｌｉｋｅ受容体７または８アゴニストとコレステロールの結合体およびその用途
AU2020358726A1 (en) 2019-10-01 2022-04-07 Silverback Therapeutics, Inc. Combination therapy with immune stimulatory conjugates
WO2021168274A1 (en) 2020-02-21 2021-08-26 Silverback Therapeutics, Inc. Nectin-4 antibody conjugates and uses thereof
CN115666637A (zh) 2020-03-02 2023-01-31 蛋白科技先锋 基于病原体细胞壁骨架的模拟活病原体的纳米粒子及其制备方法
TW202216211A (zh) 2020-07-01 2022-05-01 美商希沃爾拜克治療公司 抗asgr1抗體共軛物及其用途
JP2023536954A (ja) 2020-08-04 2023-08-30 プロジェニア インコーポレイテッド 活性化部位が一時的に不活性化したトール様受容体７または８作用薬と機能性薬物の結合体およびその用途
WO2022031011A1 (ko) 2020-08-04 2022-02-10 성균관대학교산학협력단 동력학적으로 작용하는 아주번트 앙상블
EP4194006A1 (en) 2020-08-04 2023-06-14 Progeneer Inc. Mrna vaccine comprising adjuvant capable of kinetic control
WO2022063278A1 (zh) * 2020-09-27 2022-03-31 上海维申医药有限公司 大环tlr7激动剂、其制备方法、药物组合物及其用途

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3485225D1 (de) * 1983-08-18 1991-12-05 Beecham Group Plc Antivirale guanin-derivate.
TW552261B (en) 1996-07-03 2003-09-11 Japan Energy Corp Novel purine derivative
AUPO912997A0 (en) 1997-09-11 1997-10-02 Commonwealth Scientific And Industrial Research Organisation Antiviral agents
NZ504800A (en) 1997-11-28 2001-10-26 Sumitomo Pharma 6-Amino-9-benzyl-8-hydroxy-purine derivatives and interferon inducers, antiviral agents, anticancer agents and therapeutic agents for immunologic diseases thereof
JPH11180981A (ja) * 1997-12-19 1999-07-06 Sumitomo Pharmaceut Co Ltd 複素環誘導体
TW572758B (en) 1997-12-22 2004-01-21 Sumitomo Pharma Type 2 helper T cell-selective immune response inhibitors comprising purine derivatives
JP4189048B2 (ja) * 1997-12-26 2008-12-03 大日本住友製薬株式会社 複素環化合物
AU2003276824B8 (en) 2002-03-15 2009-01-22 The Regents Of The University Of Michigan Novel 2-amino-9-[(2-hydroxymethyl) cyclopropylidenemethyl] purines as antiviral agents
CA2497765A1 (en) * 2002-09-27 2004-04-08 Sumitomo Pharmaceuticals Co., Ltd. 8-hydroxy substituted adenine compounds and uses thereof
BRPI0611435A2 (pt) 2005-05-04 2010-09-08 Pfizer Ltd derivados de 2-amido-6-amino-8-oxopurina, composições farmacêuticas, uso e processo de preparo dos mesmos
DE102006053049A1 (de) 2006-11-10 2008-05-15 Daimler Ag Staufach mit einer Abdeckeinrichtung
EP2170888B1 (en) * 2007-06-29 2015-04-22 Gilead Sciences, Inc. Purine derivatives and their use as modulators of toll-like receptor 7
CN101239980B (zh) 2008-02-18 2011-06-22 靳广毅 免疫受体调节剂偶联体前体和偶联体及其应用
KR101687841B1 (ko) 2008-12-09 2016-12-19 길리애드 사이언시즈, 인코포레이티드 톨-유사 수용체의 조절제
KR101793300B1 (ko) * 2009-10-22 2017-11-02 길리애드 사이언시즈, 인코포레이티드 특히 바이러스성 감염의 치료에 유용한 퓨린 또는 데아자퓨린의 유도체
US20110150836A1 (en) 2009-12-22 2011-06-23 Gilead Sciences, Inc. Methods of treating hbv and hcv infection
US8501724B1 (en) * 2012-01-31 2013-08-06 Pharmacyclics, Inc. Purinone compounds as kinase inhibitors
US9962388B2 (en) 2014-08-15 2018-05-08 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. Pyrrolopyrimidine compounds used as TLR7 agonist
CA2982704C (en) * 2015-05-08 2023-10-24 F. Hoffmann-La Roche Ag Sulfonimidoylpurinone compounds and derivatives for the treatment and prophylaxis of virus infection
JP7013467B2 (ja) * 2016-08-29 2022-01-31 エフ．ホフマン－ラ ロシュ アーゲー ウイルス感染の治療又は予防用の７位置換スルホンイミドイルプリノン化合物

Also Published As

Publication number Publication date
CR20190087A (es) 2019-04-30
CA3034148A1 (en) 2018-03-08
IL284255B (en) 2022-07-01
MX2021006902A (es) 2021-07-07
TW201819382A (zh) 2018-06-01
AU2021204303B2 (en) 2022-05-12
IL264710B (en) 2021-07-29
JP2022050632A (ja) 2022-03-30
ES2867849T3 (es) 2021-10-21
KR20190039829A (ko) 2019-04-15
PL3504210T3 (pl) 2021-07-05
CO2019000932A2 (es) 2019-02-08
JP7214900B2 (ja) 2023-01-30
AU2017320742B2 (en) 2021-08-05
CN109641904A (zh) 2019-04-16
MA46038B1 (fr) 2021-05-31
MY197408A (en) 2023-06-16
KR102459155B1 (ko) 2022-10-28
RU2019107957A3 (es) 2020-12-18
RU2019107957A (ru) 2020-09-29
EP3865482A1 (en) 2021-08-18
BR112019003519A2 (pt) 2019-05-21
MA46038A (fr) 2019-07-03
UA124270C2 (uk) 2021-08-18
HRP20210621T1 (hr) 2021-05-28
JP7013467B2 (ja) 2022-01-31
IL293475A (en) 2022-08-01
SG10202010520SA (en) 2020-11-27
RU2751349C2 (ru) 2021-07-13
US20190256515A1 (en) 2019-08-22
PT3504210T (pt) 2021-04-19
AU2021204303A1 (en) 2021-07-22
EP3504210B1 (en) 2021-02-24
EP3504210A1 (en) 2019-07-03
TWI671300B (zh) 2019-09-11
AU2017320742A1 (en) 2019-02-28
AU2022204697A1 (en) 2022-07-21
MX2019002129A (es) 2019-06-20
NZ750604A (en) 2024-02-23
CN109641904B (zh) 2022-01-28
US20200385387A1 (en) 2020-12-10
US10752630B2 (en) 2020-08-25
WO2018041763A1 (en) 2018-03-08
CL2019000512A1 (es) 2019-07-12
JP2019526633A (ja) 2019-09-19
KR20220147702A (ko) 2022-11-03
DK3504210T3 (da) 2021-04-26
IL284255A (en) 2021-07-29
SG11201901633WA (en) 2019-03-28
HUE053944T2 (hu) 2021-08-30
US20180072730A1 (en) 2018-03-15
SI3504210T1 (sl) 2021-08-31
RS61752B1 (sr) 2021-05-31
US10233184B2 (en) 2019-03-19
PH12019500432A1 (en) 2019-10-21

Similar Documents

Publication Publication Date Title
PE20190476A1 (es) Compuestos sulfonimidoilpurinona 7-sustituidos y derivados para el tratamiento y la profilaxis de la infeccion virica
CL2018003492A1 (es) Hepatitis b agentes antivirales.
CL2021001288A1 (es) Heterociclos funcionalizados como agentes antivirales
CL2018002528A1 (es) Agentes anti virales de la hepatitis b.
CY1124404T1 (el) Παραγωγα χολικου οξεος ως αγωνιστες fxr/tgr5 και μεθοδοι χρησης αυτων
PE20181298A1 (es) Inhibidores de bromodominio bivalentes y usos de los mismos
PE20160686A1 (es) Nuevas dihidroquinolizinonas para el tratamiento y profilaxis de la infeccion por virus de la hepatitis b
EA202092896A1 (ru) Гетероциклические и гетероарильные соединения для лечения болезни гентингтона
PE20150776A1 (es) 6-aminoacido-heteroarildihidropirimidinas para el tratamiento y profilaxis de la infeccion del virus de la hepatitis b
CL2017001426A1 (es) Nuevos compuestos de 5-amino-6h-tiazolo[4,5-d]pirimidin-2,7-diona 3-sustituidos para el tratamiento y profilaxis de infecciones virales.
CL2016002179A1 (es) Nuevas heteroarildihidropirimidinas 6-fusionadas para el tratamiento y la profilaxis de la infección por virus de la hepatitis b.
PE20220567A1 (es) Nuevos derivados piperidinilo, un proceso para su preparacion y composiciones farmaceuticas que los contienen
CU20180011A7 (es) Composiciones farmacéuticas que comprenden compuestos derivados de diaminopirido (3,2-d) como moduladores de receptor de tipo toll
ECSP12011684A (es) Inhibidores de los virus flaviviridae.
PE20161066A1 (es) Derivados de piperidinil-indol como inhibidores del factor de complemento b y usos de los mismos
CL2013002299A1 (es) Compuestos derivados de heterociclos, inhibidores de la replicacion del virus de la hepatitis c; composicion farmaceutica que los comprende; util en el tratamiento de una infeccion por vhc. (divisional solicitud 689-2011).
EA201592126A1 (ru) 6-мостиковые гетероарилдигидропиримидины для лечения и профилактики заражения вирусом гепатита b
EA201690019A1 (ru) Производное аминотриазина и содержащая его фармацевтическая композиция
PE20191461A1 (es) Compuestos amida para el tratamiento del vih
MA37712B1 (fr) Inhibiteurs macrocycliques de virus flaviviridae
MX2010009995A (es) Heterociclos puenteados como inhibidores de la integrasa del virus de inmunodeficiencia humana.
PE20180024A1 (es) Triazolopirazinonas como inhibidores de pde1
PE20161379A1 (es) Nuevos compuestos macrociclicos
UY38383A (es) Heterociclos funcionalizados como agentes antivirales
EA201790758A1 (ru) Производные моно- или дизамещенных индолов в качестве ингибиторов репликации вирусов денге